RCUS: Arcus Biosciences, Inc. Stock

by  •  • Comments Off on RCUS: Arcus Biosciences, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 830.82
Enterprise Value ($M) 728.82
Book Value ($M) 485.00
Book Value / Share 4.58
Price / Book 1.71
NCAV ($M) 351.00
NCAV / Share 3.32
Price / NCAV 2.37

Profitability (mra)
Return on Invested Capital (ROIC) -0.44
Return on Assets (ROA) -0.22
Return on Equity (ROE) -0.40

Liquidity (mrq)
Quick Ratio 4.50
Current Ratio 4.50

Balance Sheet (mrq) ($M)
Current Assets 1,016.00
Assets 1,150.00
Liabilities 665.00
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 258.00
Operating Income -310.00
Net Income -283.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -170.00
Cash from Investing -84.00
Cash from Financing 277.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
2 days ago 13G/A BlackRock, Inc. 9.40 2.51
03-05 13D/A Gilead Sciences Inc 35.00 0.00
12-17 13D/A Rosen Terry J 4.10 -11.69
11-12 13G/A Fmr Llc 4.89 -5.52
10-17 13G/A State Street Corp 3.30 -28.97

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-25 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-11-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 o TRANSITION REPORT
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 o TRANSITION REPORT PURS
2024-05-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 o TRANSITION REPORT PUR

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-17 56,335 673,051 8.37
2025-04-16 139,950 664,466 21.06
2025-04-15 127,976 738,334 17.33
2025-04-14 279,758 1,307,873 21.39

(click for more detail)

Similar Companies
PFE – Pfizer Inc. PRGO – Perrigo Company plc
QGEN – Qiagen N.V. RFL – Rafael Holdings, Inc.
USNA – USANA Health Sciences, Inc.


Financial data and stock pages provided by
Fintel.io